EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer.

Cancer Drug Resist · 2020 · PMC8992551 · PMID 35582228

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Immunoblot of the final MD-468 tumors showed a trend for reduced EGFR activity in tumors treated with both prexasertib and erlotinib [Figure 8] .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.